Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells
{{output}}
Atacicept (TACI:Fc5) is a homodimeric fusion protein obtained through recombinant DNA technology being developed by Merck Serono SA, under license from ZymoGenetics Inc, for the potential treatment of B-cell diseases. Atacicept is undergoing phase II/III clini... ...
